MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

Home » Ocular Therapeutix eyes a $24M Series D extension | Wall Street Beat

Ocular Therapeutix eyes a $24M Series D extension | Wall Street Beat

By

MassDevice.com Wall Street Beat

Ocular Therapeutix said it closed a $23.8 million Series D extension round from existing backers for its sustained drug release technology to treat eye diseases.

The Bedford, Mass.-based medical device company said all of its current institutional investors ponied up for the round, including Polaris Ventures, Versant Ventures, SV Life Sciences, Sparta LLC, and Ascension Health Ventures.

Ocular Therapeutix is developing a punctum plug for the entry of the tear duct to release drug therapy to the surface of the eye over several months.

Sign up to get our free newsletters delivered straight to your inbox

President & CEO Amar Sawhney told MassDevice.com that the company plans to use the funds to back clinical trials of the device and hopes to then commercialize the technology in the U.S.

"There are many punctum plug-based products. We’re focused on glaucoma and post-operative inflammation using a steroid," Sawhney told us. "Generally speaking, we would be doing Phase II trials for both of those indications next year. We would potentially be doing Phase III trials and after that, obviously, [FDA] submission would take place."

Ocular Therapeutix is also awaiting word from the federal watchdog agency on the pre-market approval application for its ReSure sealant, a hydrogel used to protect ocular incisions following eye surgery.

"We’re very excited. We expect to have some sort of approval some time later this year," Sawhney said.

 Organovo drums up $8M
Tissue engineering firm Organovo raised nearly $7.7 million from a group of 109 unnamed investors.
Read more

 iRobot shares soar on FDA clearance for RP-VITA remote presence ‘bot

Shares of iRobot (NSDQ:IRBT)
jumped nearly 20% last week on the heels of FDA clearance for the RP-VITA remote presence robot it co-developed with InTouch Health. IRBT shares jumped 19.1% to a peak of $23.85 on Jan. 25; shares were trading at $23.50 as of about 2:0 p.m. today, up 1.1%.

 Given Imaging lands reimbursement code
Given Imaging (NSDQ:GIVN) said it won a new reimbursement code for its SmartPill gastroenteric imaging device. The 2013 National Average Medicare Physician Fee for the device is $1,188.93. GIVN shares were up 6.0% to $16.80 apiece as of about 2:30 p.m. today.
Read more

 Cardica’s back in NASDAQ’s good graces

Cardica (NSDQ:CRDC) said it’s back in compliance with the NASDAQ stock exchange’s market capitalization minimum of $50 million. CRDC shares were down 1.9% to $1.53 each as of about 2:20 p.m. today for a market cap of $56.5 million.
Read more

 Analysts’ ups and downs

  • Abbott (NYSE:ABT): Leerink Swann reiterates "market perform" rating, raises price target to $32-$34 from $30.
  • Allergan (NYSE:AGN): Bank of America Merrill Lynch raises price target from $106 to $110, maintains “buy” rating.
  • Baxter (NYSE:BAX): Leerink Swann maintains "outperform" rating, $74 price target.
  • Covidien (NYSE:COV): Barclays Equity Research reiterates "overweight" rating, $64 price target; Citigroup reiterates "buy" rating, raises price target from $64 to $71; Goldman Sachs reiterates "neutral" rating, raises price target from $63 to $66; Leerink Swann maintains "outperform" rating, raises price target to $71 from $65.
  • Haemonetics (NYSE:HAE): Barrington downgrades from “outperform” to “market perform” rating.
  • Intuitive Surgical (NSDQ:ISRG): Barrington maintains “outperform” rating, $650 price target; Cantor Fitzgerald maintains "hold" rating, raises price target from $525 to $550.
  • Medtronic (NYSE:MDT): Wunderlich Securities downgrades from “buy” to “hold” rating, maintains $46 price target.
  • ResMed (NYSE:RMD): Bank of America downgrades from “buy” to “neutral” rating.
  • Sirona Dental Systems (NSDQ:SIRO): Cantor Fitzgerald reiterates "buy" rating, raises price target from $72 to $75.
  • St. Jude Medical (NYSE:STJ): Leerink Swann reiterates "outperform" rating, ~$50 price target; TheStreet Ratings reiterates "hold" rating.
  • Stryker (NYSE:SYK): Leerink Swann maintains "outperform" rating, raises price target to $74 from $61.

In case you missed it

RSS From Medical Design & Outsourcing

  • COVID-19 immunity test developers at MIT seek diagnostic manufacturer
    MIT researchers have developed a device for predicting an individual’s COVID-19 immunity and are looking for a diagnostic company to get it manufactured in large numbers and approved by the FDA. The lateral flow test uses the same technology as at-home rapid antigen COVID-19 tests to measure neutralizing antibodies for SARS-CoV-2 in a blood sample,… […]
  • GE Healthcare picks AI imaging startups for inaugural Edison Accelerator
    GE Healthcare and Nex Cubed have selected seven companies focused on artificial-intelligence-augmented medical imaging for the first cohort of the Edison Accelerator in Canada. The companies will be matched with mentors and test their technologies with GE’s new Edison Digital Health Platform over the next three months. The program will end with innovation showcase presentations… […]
  • Boston Scientific whistleblower launches corruption investigation
    Boston Scientific (NYSE:BSX) is investigating claims that the company violated the U.S. Foreign Corrupt Practices Act in Vietnam. Marlborough, Massachusetts–based Boston Scientific disclosed receipt of a whistleblower’s allegations in its latest filing with the Securities and Exchange Commission. “In March 2022, the company received a whistleblower letter alleging Foreign Corrupt Practices Act violations in Vietnam.… […]
  • 5 essential leadership lessons from Cathy Burzik for medtech’s next generation of women leaders
    Cathy Burzik, a seasoned senior executive in the healthcare industry, has successfully led major medical device, diagnostic, diagnostic imaging and life sciences businesses. Cathy Burzik, CFB Interests (as told to MedExecWomen co-founder Maria Shepherd) One key to being a successful women leader in MedTech: “Play nice, but play to win.” Cathy Burzik, who received a… […]
  • Stratasys plans to buy Covestro’s additive manufacturing business
    Stratasys (Nasdaq:SSYS) said today that it has a deal to purchase the additive manufacturing materials business of Covestro. The deal includes R&D facilities and activities, global development and sales teams across Europe, the U.S. and China, a portfolio of approximately 60 additive manufacturing materials, and hundreds of patents and patents pending, Stratasys said in a… […]
  • New implant design prevents scar tissue without drugs, MIT says
    Mechanically inflating and deflating an implantable device for 10 minutes a day prevents immune cells from building the scar tissue that has been a major obstacle for artificial pancreas researchers. That’s according to new findings from a team of MIT engineers who built mechanical deflection into a two-chambered, soft polyurethane device tested on mice. By… […]
  • Blue Spark’s TempTraq catches fevers faster. Fever prediction is next.
    Blue Spark Technologies developed the first wireless continuous temperature monitor patch, TempTraq, to enable faster fever detection than standard manual readings every four hours. Westlake, Ohio-based Blue Spark is now looking at fever prediction rather than just detecting them. The R&D team is working on developing an AI neural network model built on the company’s… […]
  • Harvard researchers plan to sell at-home, PCR-grade COVID testing system
    The Harvard University researchers who developed an ultrasensitive, PCR-grade nucleic acid detection technology plan to commercialize it as a portable COVID-19 test. Harvard Medical School professor Peng Yin, who also leads the Wyss Institute for Biologically Inspired Engineering’s Molecular Robotics Initiative, founded 3EO Health to sell the device. “In order to optimize the value of… […]
  • FDA reports sterilization challenge progress as EPA takes aim at EtO emissions
    The FDA offered an update on its efforts to make medical device sterilization safer as the EPA identified 23 U.S. facilities where use of ethylene oxide (EtO) presents a risk to communities. The FDA said it is similarly concerned about unsafe EtO emissions and highlighted work with the medical device industry to reduce EtO usage… […]
  • AdvaMed defends EtO facilities on EPA’s cancer risk list
    The Advanced Medical Technology Association (AdvaMed) today reacted to the EPA’s listing of commercial sterilization facilities causing elevated risks of cancer with a defense of the facilities and a call for more research. AdvaMed CEO and President Scott Whitaker said all of the listed facilities are in compliance with regulations and warned against closures. “The… […]
  • EPA flags high-cancer-risk EtO sterilization facilities across the country
    The EPA today identified nearly two dozen U.S. cities where commercial sterilizers using ethylene oxide (EtO) contribute to an elevated cancer risk for residents of surrounding communities. EtO is used on about 20 billion medical devices each year — or about half of all sterile medical devices —  and in some cases it’s the only… […]

Leave a Reply